First safety test of new cancer drug for chinese patients
NCT ID NCT06549816
Summary
This study tested the safety and how the body processes an experimental drug called SGN-B6A in Chinese patients with advanced solid tumors. It involved a small group of 6 participants who had cancers like lung, head and neck, or stomach cancer that had stopped responding to standard treatments. The main goal was to identify side effects and understand how the drug moves through the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430023, China
Conditions
Explore the condition pages connected to this study.